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 20 
Deregulation of kinase function is associated with several diseases. Therefore, 21 
efforts have been focused on selective targeting of these aberrant kinases in different 22 
disease models. These efforts received a boost with the success of ABL kinase 23 
inhibitor, Imatinib (also known as Gleevec or STI571), the first kinase targeted therapy 24 
in chronic myeloid leukemia (CML). Though Imatinib was not curative in CML; the long 25 
term survival of CML patients is now similar to that of age matched population.1 Imatinib 26 
was not as successful in other malignancies driven by its target kinases but it provided 27 
the impetus for expanding the repertoire of kinase targeted therapies in oncology. In a 28 
short span of 15 years, 28 small molecule kinase inhibitors have been approved by 29 
Food and Drug Administration (FDA) for cancer therapy making them possibly the 30 
fastest growing class of therapeutics. While on one hand the number of potential kinase 31 
targets and their inhibitors in different stages of clinical trials are expanding; on the other 32 
hand the kinase inhibitors are finding application in areas other than oncology. Given 33 
their importance in immune cell signaling, several of the kinase inhibitors developed for 34 
cancer are being applied to disorders involving immune cell hyperactivation (Table 1) 35 
and more recently for selective reactivation of immune cell function.  36 
  37 
Majority of the kinase inhibitors in clinical trials act by suppressing cytokine 38 
dependent immune cell activation frequently observed in auto-immune and 39 
inflammatory disorders. Targeting of Janus Kinase 2 (JAK2) and JAK3 has been the 40 
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most successful in immunological diseases as they are utilized by multiple cytokines 41 
that have either common gp130 or γ chain (Figure 1, Table 1). Thus a single inhibitor is 42 
able to block signaling from multiple cytokines involved in inflammatory and 43 
autoimmune disorders. JAK3 inhibitor (CP-690550/ Tofacitinib/ Xeljanz) has been 44 
approved by FDA for treatment of rheumatoid arthritis and it has entered post marketing 45 
surveillance (Table 1). It is now being clinically evaluated in other autoimmune disorders 46 
that involve hyperactivated cytokine signaling and immune cell activation (Table 1). In 47 
addition to the clinical trials underway for treatment of auto-immune and inflammatory 48 
diseases, potential application of kinase inhibitors in other areas such as immune 49 
response to microbial or viral infections is also being explored in pre-clinical studies. 50 
Gefitinib, a FDA approved receptor tyrosine kinase inhibitor has shown pre-clinical 51 
promise in restricting Mycobacterium tuberculosis growth through increased lysosomal 52 
targeting and suppressing STAT3 activation.2 Similarly using kinome profiling of human 53 
cytomegalovirus infected cells, researchers have identified potential kinase inhibitors 54 
that could find application as anti-virals in clinic in the near future.3 Similar studies being 55 
carried out with other microbes and viruses to restrict their ability to survive and 56 
replicate by host directed kinase inhibitors will be extremely helpful in countering 57 
increasing drug resistance in infections.  58 
 59 
In oncology practice, it has been recently shown that anti-tumor effects of 60 
Dasatinib, a tyrosine kinase inhibitor, were mediated in part through increase in 61 
frequency of peripheral and intra-tumoral CD8+ T cells.4 Though the mechanism of 62 
action is not clear, the CD8+ T cells showed increase in programmed death 1 (PD-1) 63 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
expression with reduced cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) 64 
expression. These molecules act as checkpoints to limit immune response to self and 65 
are utilized by tumors to evade the immune surveillance. Therefore, checkpoint-66 
blockade therapies reactivate patient’s immune system through inhibition of CTLA-4 or 67 
(PD-1) activated pathways. Three checkpoint inhibitors have been approved - 68 
Ipilimumab (anti-CTLA-4), pembrolizumab (anti-PD-1), and nivolumab (anti-PD-1) as 69 
single agents or in combination for the treatment of advanced melanoma and refractory 70 
non-small cell lung cancer. However, only 30-40% patients respond to these immune 71 
checkpoint blockade therapies. Moreover it is not possible to accurately predict as to 72 
which patients are likely to respond. In general, patients with higher intra-tumoral T cell 73 
infiltration show a better response with checkpoint blockade therapies. In an analysis of 74 
genetic and transcriptional factors from responder and non-responder patients, 75 
immunosuppressive and monocyte chemotactic genes were found to be amongst the 76 
differentially expressed genes between the 2 groups.5 This indicates that tumors 77 
actively recruit monocytes and macrophages to modulate the tumor microenvironment 78 
in a manner that suppresses anti-tumor immune responses and makes them refractory 79 
to anti-immune checkpoint therapies.  80 
 81 
Idelalisib, the first FDA approved drug to target a lipid kinase, phosphoinositide 3-82 
kinase δ isoform (PI3K δ) has been shown to act both on tumor cells and their 83 
microenvironment.6   As the PI3K pathway regulates multiple aspects of cancer growth 84 
and metastasis through PI3K-AKT-mTOR axis, they are one of the most sought after 85 
targets in oncology. IPI-549, a PI3K-γ specific inhibitor is a new member to join the list 86 
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of PI3K inhibitors in clinical trials for melanoma. Interestingly, IPI-549 had no effect on 87 
growth or viability of melanoma cells but appeared to target the myeloid cells within the 88 
tumor microenvironment to enhance anti-tumor cytotoxic T cell responses.7  Inhibition of 89 
the PI3K- γ kinase in the CD11b+F4/80+CD206+ M2 type tumor associated myeloid 90 
suppressor cells by IPI-549 converted them to CD11b+F4/80+MHCII+ inflammatory M1 91 
type cells that are efficient at tumor antigen presentation and lead to upregulation of PD-92 
1 and CTLA4 expression on CD8+ T cells.7 Combination of IP1-549 with anti-PD-1 or 93 
anti-CTLA4 therapies was shown to overcome the innate resistance in melanoma, 94 
breast and lung cancer models.7 Complete remissions in 30% of breast cancer and 80% 95 
of melanoma bearing mice was observed. Interestingly, the tumor free mice also 96 
showed development of an immune memory and were resistant to tumor re-97 
implantation.7 Similar association between a pro-inflammatory immune profile and 98 
increased survival has observed in human papilloma virus+ (HPV) head and neck 99 
squamous cell carcinoma (HNSCC) patients.8 The tumor infiltrating myeloid cells 100 
mediate immunosuppression through PI3K- γ-AKT-mTOR mediated activation of NF-κB 101 
and CCAAT/enhancer binding protein β (C/EBPβ).8  In this model of HPV+ HNSCC too, 102 
inhibition or loss of PI3K- γ was associated with enhanced antigen presentation, CD8+ T 103 
cell anti-tumor response and demonstrated synergism with anti-PD1 therapy.8 These 104 
results advocate for targeting of myeloid suppressor cells in the tumor 105 
microenvironment and bring hope for higher success with checkpoint blockade immune 106 
therapy.  107 
 108 
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Though the expanding universe of potential target kinases and their inhibitors in 109 
the clinic has brought hope to patients, a word of caution is required. Most of these 110 
inhibitors have been in clinical practice for less than a decade and their long term 111 
effects are poorly understood. Suppression of PI3K-δ has been reported to increase 112 
genomic instability due to increased expression of activation-induced cytidine 113 
deaminase (AID).9  While PI3K-δ inhibitors (Idelalisib, duvelisib, ibrutinib) inhibit 114 
proliferation of naïve and leukemic B cells, they also induce increase in somatic 115 
mutations, translocations and development of AID dependent tumors.9 It raises 116 
important questions regarding the suitability of these inhibitors for long term use in 117 
patients. However, given the limited treatment options that patients have, it is almost 118 
certain that kinase inhibitors will be the mainstay in oncology clinical practice and will 119 
continue to expand into other disease areas. 120 
 121 
Conflict of Interest: The authors have no potential conflict of interest. 122 
Acknowledgements: RP is funded by NIH T32DK-07519 and research in RK lab is 123 
supported by R01HL077177, R01HL081111, R01CA173852, R01CA134777 and Riley 124 
Children’s foundation. 125 
References: 126 
1. Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life 127 
Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life 128 
Expectancy of the General Population. J Clin Oncol 2016, 34:2851-2857. 129 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2. Sogi MK, Lien KA, Johnson JR, Krogan NJ, Stanley SA. The tyrosine kinase inhibitor 130 
Gefitinib restricts Mycobacterium tuberculosis growth through increased lysosomal 131 
biogenesis and modulation of cytokine signaling. ACS Infect Dis 2017, 132 
10.1021/acsinfecdis.7b00046 133 
3. Arend KC, Lenarcic EM, Vincent HA, Rashid N, Lazear E, McDonald IM, et al. 134 
Kinome profiling identifies druggable targets for novel Human Cytomegalovirus (HCMV) 135 
antivirals. Mol Cell Proteomics 2017, 4 suppl 1:S263-S276. 136 
4. Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vähä-Koskela M, et al. Dasatinib 137 
Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several 138 
Murine Solid Tumor Models. Cancer Immunol Res 2017, 5: 157-169. 139 
5. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic 140 
and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic 141 
Melanoma. Cell 2016, 165:35-44. 142 
6. Maffei R, Fiorcari S, Martinelli S, Potenza L, Luppi M, Marasca R. Targeting 143 
neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and 144 
idelalisib. J Hematol Oncol 2015, 8:60. 145 
7. De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. 146 
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in 147 
myeloid cells. Nature 2016, 539:443-447. 148 
8. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. 149 
PI3Kgamma is a molecular switch that controls immune suppression. Nature 2016, 150 
539:437-442. 151 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9. Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, et al. 152 
Phosphatidylinositol 3-kinase delta blockade increases genomic instability in B cells. 153 
Nature 2017, 542:489-493. 154 
 155 
  156 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1: Kinase inhibitors in active clinical trials for Immune disorders 157 
Drug Name Target Disease Indication Clinical Trial 
Identifier 
Stage of 
developmen
t 
INCB018424 
(Ruxolitinib) 
JAK 1/2 Atopic Dermatitis NCT03011892 Phase 2 
INCB018424 
(Ruxolitinib) 
JAK 1/2 Graft vs Host Disease  NCT02997280 
NCT02953678
NCT02913261 
NCT03112603 
Phase 2 
 
Phase 3 
CDZ173 PI3Kδ Activated PI3Kdelta 
Syndrome (APDS); 
p110delta-activating 
Mutation Causing Senescent 
T Cells, Lymphadenopathy 
and Immunodeficiency 
(PASLI) 
NCT02435173 
 
Phase 2/3 
PF-06650833 IRAK4 Rheumatoid Arthritis NCT02996500 Phase 2 
CP-690550  
(Tofacitinib, 
Xeljanz) 
JAK 3 Rheumatoid Arthritis NCT02831855  
NCT02092467 
NCT02321930 
NCT02157012 
NCT02984020 
NCT03011281 
Phase 4, 
post 
marketing 
surveillance 
CP-690550  
(Tofacitinib, 
Xeljanz) 
JAK 3 Juvenile Idiopathic  
Arthritis  
NCT02592434 
NCT01500551 
NCT03000439 
Phase 3 
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GSK2982772  RIP1K Rheumatoid Arthritis NCT02858492 Phase 2 
     
Pacritinib JAK 2, 
FLT3 
Graft Vs Host Disease NCT02891603 Phase 1/2 
Imatinib mesylat
e (Gleevec) 
ABL, 
BCR-
ABL, 
PDGFRA
, c-KIT 
Graft Vs Host Disease NCT01898377 Phase 2 
CP-690550  
(Tofacitinib, 
Xeljanz) 
JAK 3 Systemic Lupus Erythematos
us 
NCT02535689 
NCT03159936 
Phase 1 
 158 
The clinical trial registry at https://clinicaltrials.gov was queried for active (open) clinical 159 
trials with kinase inhibitors in immune diseases. JAK – Janus Kinase; PI3K - 160 
Phosphoinositide 3-Kinase; IRAK - Interleukin-1 Receptor Associated Kinase; RIP1K - 161 
Receptor-Interacting Protein-1 Kinase; FLT3 - Fms Related Tyrosine Kinase 3; ABL - 162 
Abelson murine leukemia viral oncogene homolog 1; BCR – B Cell Receptor; PDGFRA 163 
- Platelet-Derived Growth Factor Receptor Alpha  164 
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Figure 1: JAK2 and JAK3 inhibitors in clinical trials for immunological disorders. JAK2 165 
and JAK3, non-receptor tyrosine kinases associate with different cytokine receptors 166 
have been targets in diseases such as rheumatoid arthritis, graft versus host disease, 167 
atopic dermatitis and systemic lupus erythematosus.   168 
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JAK2 JAK3
Type II cytokine receptor family
gp130 receptor family
γc Cytokine receptor family
Ruxolitinib
(INCB018424)
Pacritinib
(SB1518)
Tofacitinib
(Xeljanz, CP-690550 )
Decernotinib
(VX-509)
Baricitinib
(INCB028050)
